Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc.
Your view on FULC
Overview
What the company does, where it operates, and who runs it.
About Fulcrum Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alexander C. Sapir
- Headquarters
- 26 Landsdowne Street, Cambridge, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alexander C. Sapir
- Headquarters
- 26 Landsdowne Street, Cambridge, MA, US
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases.
Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies.
Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Fulcrum Therapeutics, Inc. from FRC's valuation model, read against the market price. FULC last traded at $3.77; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Fulcrum Therapeutics, Inc.. Starting points for Fulcrum Therapeutics, Inc.: EPS -$1.00, beta 2.77 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Fulcrum Therapeutics, Inc.. Fulcrum Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Fulcrum Therapeutics, Inc.. Trailing twelve-month EPS for Fulcrum Therapeutics, Inc. stands at -$1.00. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$9.62
average of 8 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy1
- Hold5
- Sell3
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.08 | -$0.30 | -$0.60 | -$0.12 |
| Low estimate | -$0.08 | -$0.30 | -$0.81 | -$0.26 |
| High estimate | -$0.08 | -$0.30 | -$0.49 | -$0.04 |
| No. of analysts | 1 | 1 | 3 | 5 |
| Year-ago EPS | -$0.31 | -$0.25 | -$1.18 | — |
| Growth | +74.2% | -18.0% | +49.2% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | $0.00 | $311890.00 | $361.24M |
| Low estimate | $0.00 | $0.00 | $311890.00 | $361.24M |
| High estimate | $0.00 | $0.00 | $311890.00 | $361.24M |
| No. of analysts | 0 | 0 | 5 | 4 |
| Year-ago revenue | $0.00 | $0.00 | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 14, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Fulcrum Therapeutics, Inc.. Fulcrum Therapeutics, Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ADCTADC Therapeutics S.A.Biotechnology$171M
- BCYCBicycle Therapeutics plcBiotechnology$236M
- CMPXCompass Therapeutics, Inc.Biotechnology$139M
- LCTXLineage Cell Therapeutics, Inc.Biotechnology$231M
- LXRXLexicon Pharmaceuticals, Inc.Biotechnology$797M
- NGNENeurogene Inc.Biotechnology$378M
- NMRANeumora Therapeutics, Inc. Common StockBiotechnology$81M
- OCGNOcugen, Inc.Biotechnology$281M
More Biotechnology companies
- SANASana Biotechnology, Inc.NASDAQ$605M
- SCNIScinai Immunotherapeutics Ltd.NASDAQ$206,775
- SCNLFScancell Holdings plcOTC$189M
- SCPSScopus BioPharma Inc.OTC$16,833
- SCPXScorpius Holdings, Inc.OTC$130,071
- SCTXScribe Therapeutics Inc.NASDAQ$265M
- SEERSeer, Inc.NASDAQ$88M
- SEOVFSernova Corp.OTC$34M
- SEPNSepterna, Inc.NASDAQ$2.0B
- SEPSFAsep Medical Holdings IncOTC$121,249
- SERSerina Therapeutics, Inc.AMEX$21M
- SGMOQSangamo Therapeutics, Inc.OTC
ETFs holding Fulcrum Therapeutics, Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- IWMiShares Russell 2000 ETF$76.6B in assets0.01%
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- IWNiShares Russell 2000 Value ETF$13.9B in assets0.02%
- SBIOALPS Medical Breakthroughs ETF$187M in assets0.19%
- PINKSimplify Health Care ETF$352M in assets0.16%
- IWCiShares Micro-Cap ETF$1.2B in assets0.06%
- AVSCAvantis U.S. Small Cap Equity ETF$3.2B in assets0.02%
Largest holders first, then the funds most concentrated in FULC.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Fulcrum Therapeutics, Inc., and how their positions are changing. At a $287.6M market value, institutional positions materially move Fulcrum Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Fulcrum Therapeutics, Inc. executives and directors. Shares of Fulcrum Therapeutics, Inc. have traded between $2.31 and $10.11 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Fulcrum Therapeutics, Inc.. Coverage tracks Fulcrum Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Fulcrum Therapeutics, Inc.